KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Current Assets (2016 - 2025)

Historic Current Assets for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to $1.2 billion.

  • NovoCure's Current Assets rose 954.89% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 954.89%. This contributed to the annual value of $1.1 billion for FY2024, which is 697.65% up from last year.
  • As of Q3 2025, NovoCure's Current Assets stood at $1.2 billion, which was up 954.89% from $1.1 billion recorded in Q2 2025.
  • Over the past 5 years, NovoCure's Current Assets peaked at $1.2 billion during Q3 2025, and registered a low of $1.0 billion during Q1 2024.
  • Moreover, its 5-year median value for Current Assets was $1.1 billion (2025), whereas its average is $1.1 billion.
  • Its Current Assets has fluctuated over the past 5 years, first soared by 17876.08% in 2021, then plummeted by 792.35% in 2024.
  • NovoCure's Current Assets (Quarter) stood at $1.1 billion in 2021, then increased by 3.54% to $1.1 billion in 2022, then decreased by 6.94% to $1.0 billion in 2023, then increased by 6.98% to $1.1 billion in 2024, then rose by 8.43% to $1.2 billion in 2025.
  • Its last three reported values are $1.2 billion in Q3 2025, $1.1 billion for Q2 2025, and $1.1 billion during Q1 2025.